Navigation Links
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Date:4/27/2009

inherent in the Orexigen business, including, without limitation: the clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials, and the FDA may not agree with the Company's interpretation of efficacy and safety results; the potential that earlier clinical trials may not be predictive of future results; Contrave may not receive regulatory approval on a timely basis or at all; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Refo
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
2. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
9. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... PTBI, PTBIW), a biopharmaceutical company advancing patient care in ... offering of 3,500,000 shares of common stock, and warrants ... common stock, at an offering price of $4.00 per ... per share exercise price of $5.00, are exercisable immediately, ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this ... James L. Sherley, director of the Adult Stem Cell ... an often overlooked and under appreciated unique property of ... by Distributed Stem Cells: Misunderstood in the Past, Important ... to congress participants. He gave the address at ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... YORK, Oct. 25 American Oriental,Bioengineering, Inc. (NYSE: ... and nutraceutical products in China, today,announced that it plans ... 5, 2007 after the market close. The company ... at 4:30 pm,ET to discuss its fiscal third quarter ...
... (Nasdaq: KOSN ) today announced that it ... October 31, 2007, beginning at approximately,7:30 a.m. Eastern ... by Kosan,s Executives, Robert G. Johnson, Jr., M.D., ... Ph.D., Senior,Vice President, Drug Discovery and Preclinical Development, ...
... Codexis, Inc., a private,biotechnology company and leading ... of Codexis Laboratories Singapore,Pte. Ltd. (CLS). CLS is ... an expansion of the company,s research and development ... the company,s pharmaceuticals business in,both the innovator and ...
Cached Biology Technology:American Oriental Bioengineering Announces Reporting Date for Third Quarter 2007 Financial Results 2Kosan Biosciences to Host Research & Development Day on October 31, 2007 2Kosan Biosciences to Host Research & Development Day on October 31, 2007 3Codexis Opens Singapore Laboratory 2
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may ... as Acuity Market Intelligence reports that the long ... open. Acuity forecasts that intensifying demand for smart ... biometrics will drive a global market of 2.5 ... by 2020.   According to ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... the story. A young athlete who seems no different from ... under the baleful sun of a blistering summer day. ... a gene mutation that makes them particularly sensitive to heat, ... Medicine ( http://www.bcm.edu ) may have identified a molecule ...
... living cells do is carried out by "molecular machines" ... some biological function. How the minute steps of evolution produced ... target for creationists. In a study published early online ... of scientists from the University of Chicago and the University ...
... new University of Florida study shows genomes of a ... phenomenon that may have far-reaching evolutionary consequences. Published ... National Academy of Sciences , the study is the ... a recently formed plant species following whole genome doubling, ...
Cached Biology News:Exercise in a pill may protect against extreme heat sensitivity 2Evolution of complexity recreated using 'molecular time travel' 2Evolution of complexity recreated using 'molecular time travel' 3Evolution of complexity recreated using 'molecular time travel' 4UF research on newly formed plants could lead to improved crop fertility 2UF research on newly formed plants could lead to improved crop fertility 3
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Biology Products: